[go: up one dir, main page]

MX336145B - Metodo para el tratamiento de insuficiencia cardiaca cronica. - Google Patents

Metodo para el tratamiento de insuficiencia cardiaca cronica.

Info

Publication number
MX336145B
MX336145B MX2012010249A MX2012010249A MX336145B MX 336145 B MX336145 B MX 336145B MX 2012010249 A MX2012010249 A MX 2012010249A MX 2012010249 A MX2012010249 A MX 2012010249A MX 336145 B MX336145 B MX 336145B
Authority
MX
Mexico
Prior art keywords
heart failure
chronic heart
treating chronic
methods
relaxin
Prior art date
Application number
MX2012010249A
Other languages
English (en)
Inventor
Dennis R Stewart
Elaine Unemori
Sam L Teichman
Martha Jo Whitehouse
Thomas Dschietzig
Original Assignee
Corthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corthera Inc filed Critical Corthera Inc
Publication of MX336145B publication Critical patent/MX336145B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento de los sujetos humanos que padecen insuficiencia cardiaca crónica. Los métodos descritos en la presente emplean la administración de relaxina. Una relaxina humana H2 farmacéuticamente activa para usarse en el tratamiento de insuficiencia cardiaca crónica en donde la relaxina está adaptada para ser administrable a un sujeto que tiene insuficiencia cardiaca clase II o clase III de acuerdo con la clasificación de la Asociación Cardiaca de Nueva York de insuficiencia cardiaca, al inicio de la administración a una cantidad terapéuticamente efectiva para reducir la frecuencia o duración de la hospitalización del sujeto, comparado a un tratamiento sin dicha relaxina, donde la frecuencia de descompensaciones es reducida a comparación de un tratamiento sin relaxina, y en donde dicha relaxina está formulada por una dosis fija de 10 a 960 µg/kg/día.
MX2012010249A 2008-05-16 2009-05-15 Metodo para el tratamiento de insuficiencia cardiaca cronica. MX336145B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US19054508P 2008-08-28 2008-08-28
US20124008P 2008-12-08 2008-12-08
PCT/US2009/044247 WO2009140657A2 (en) 2008-05-16 2009-05-15 Method of treating chronic heart failure

Publications (1)

Publication Number Publication Date
MX336145B true MX336145B (es) 2016-01-08

Family

ID=41319370

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012010249A MX336145B (es) 2008-05-16 2009-05-15 Metodo para el tratamiento de insuficiencia cardiaca cronica.
MX2010012502A MX2010012502A (es) 2008-05-16 2009-05-15 Metodo para el tratamiento de insuficiencia cardiaca cronica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2010012502A MX2010012502A (es) 2008-05-16 2009-05-15 Metodo para el tratamiento de insuficiencia cardiaca cronica.

Country Status (10)

Country Link
US (3) US20110144019A1 (es)
EP (2) EP2288366A4 (es)
JP (3) JP2011520917A (es)
CN (2) CN104815319A (es)
AU (1) AU2009246112B2 (es)
BR (1) BRPI0912559A2 (es)
CA (1) CA2724535A1 (es)
MX (2) MX336145B (es)
RU (1) RU2512933C2 (es)
WO (1) WO2009140657A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA022948B1 (ru) 2008-05-16 2016-03-31 Кортера, Инк. Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью
JP5970380B2 (ja) * 2010-03-10 2016-08-17 ザ ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド リラキシンによるアクアポリンの調節
EP2646572B1 (en) * 2010-12-01 2017-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic and treatment of chronic heart failure
MX2014000316A (es) * 2011-07-08 2014-02-19 Bayer Ip Gmbh Proteinas de fusion liberadoras de relaxina y usos de las mismas.
US9434780B2 (en) * 2011-08-04 2016-09-06 Relaxera Pharma Gmbh & Co. Kg I.G. Process for preparing human relaxin-2
WO2013033324A2 (en) 2011-08-31 2013-03-07 University Of Florida Research Foundation, Inc. Materials and methods for modulating activity of bone marrow derived cells
WO2013096534A1 (en) * 2011-12-21 2013-06-27 Nuclea Biotechnologies, Inc. Congestive heart failure biomarkers
BR112014020127A2 (pt) * 2012-02-14 2020-06-30 The Regents Of The University Of Calefornia métodos para tratamento, melhoramento ou proteção (prevenção) de um indivíduo ou um paciente, e de uma disfunção, uma doença, uma infecção ou uma condição, e, método para suprimir o ganho de peso, ou suprimir o apepite, ou estimular ou iniciar a perda de peso
CA2898571A1 (en) * 2013-01-25 2014-07-31 Cardiorentis Ltd. Methods of treating cardiovascular indications
CA2928754A1 (en) * 2013-11-07 2015-05-14 Shanghai Hengrui Pharmaceutical Co., Ltd. Human relaxin analogue, pharmaceutical composition of same, and pharmaceutical application of same
US10500227B2 (en) * 2014-12-03 2019-12-10 University Of Cincinnati Bioactive gas-encapsulated echogenic liposomes and methods for treating cardiovascular disease
US11161891B2 (en) 2015-12-09 2021-11-02 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
BR112019016139A2 (pt) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company polipeptídio de relaxina modificada compreendendo um melhorador farmacocinético e usos do mesmo
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
JP7541003B2 (ja) * 2018-11-20 2024-08-27 ウニベルジテート ハイデルベルク 心不全の治療及び予防における使用のためのリラキシン受容体１
US12226455B2 (en) 2019-11-16 2025-02-18 Relaxera Pharmazeutische Gmbh & Co. Kg Medical composition for treating cardiac wasting and cachexia
IL300367A (en) * 2020-08-05 2023-04-01 Asklepios Biopharmaceutical Inc Methods for the treatment of heart disorders and heart failure and administration of AAV vectors
RU2748529C1 (ru) * 2020-09-01 2021-05-26 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Способ определения этиологии хронической сердечной недостаточности
WO2024121362A1 (en) * 2022-12-09 2024-06-13 Astrazeneca Ab Dosing regimens using heterodimeric relaxin fusions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5166191A (en) 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
WO1995000645A2 (en) 1993-06-21 1995-01-05 Genentech, Inc. Process for producing relaxin
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
RU2213559C2 (ru) * 2000-01-26 2003-10-10 Тюменская государственная медицинская академия Способ лечения больных хронической сердечной недостаточностью на фоне ишемической болезни сердца
DE10155843A1 (de) * 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US20070202080A1 (en) * 2004-03-30 2007-08-30 Industry-University Cooperation Foundation Yonsei Gene Delivery System Containing Relaxin Gene And Pharmaceutical Composition Using Relaxin
WO2007008907A2 (en) * 2005-07-11 2007-01-18 Abbott Laboratories Methods for determining how to treat congestive heart failure
US8492329B2 (en) 2007-07-12 2013-07-23 Compugen Ltd. Bioactive peptides and methods of using same
EA022948B1 (ru) * 2008-05-16 2016-03-31 Кортера, Инк. Лечение релаксином одышки, ассоциированной с острой сердечной недостаточностью

Also Published As

Publication number Publication date
CA2724535A1 (en) 2009-11-19
US20140005112A1 (en) 2014-01-02
JP2011520917A (ja) 2011-07-21
AU2009246112B2 (en) 2013-05-02
EP2288366A2 (en) 2011-03-02
JP2017061453A (ja) 2017-03-30
CN104815319A (zh) 2015-08-05
AU2009246112A1 (en) 2009-11-19
WO2009140657A3 (en) 2010-01-07
WO2009140657A2 (en) 2009-11-19
US20160287672A1 (en) 2016-10-06
EP3150219A1 (en) 2017-04-05
RU2010151470A (ru) 2012-06-27
US20110144019A1 (en) 2011-06-16
BRPI0912559A2 (pt) 2015-10-13
RU2512933C2 (ru) 2014-04-10
MX2010012502A (es) 2011-04-11
JP2014237648A (ja) 2014-12-18
EP2288366A4 (en) 2012-05-02
CN102026649A (zh) 2011-04-20

Similar Documents

Publication Publication Date Title
MX336145B (es) Metodo para el tratamiento de insuficiencia cardiaca cronica.
UA99953C2 (uk) Лікування релаксином задишки, асоційованої з гострою серцевою недостатністю
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
MX2019005130A (es) Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente.
BR112014003117A2 (pt) inibidores da corrente funny (if) para uso em um método de tratamento e prevenção de insuficiência cardíaca em felino
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
MY174894A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
PH12013500411A1 (en) Treatment of myocardial infarction using tgf - beta antagonists
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
EA201390530A1 (ru) Способ получения сополимера натрийкарбоксиметилцеллюлозы и госсипола и его применение в комплексной терапии пациентов с аутистическими расстройствами и когнитивными нарушениями
MX2011009804A (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo.
WO2014049438A3 (en) Method of non-invasive determination of glucose concentration in blood and device for the implementation thereof
GB0806047D0 (en) Treatment of heart failure
AU2016219717A1 (en) Treating dyspnea associated with acute heart failure with relaxin
PH12016500711A1 (en) Method of treating dyspnea associated with acute heart failure
TN2010000504A1 (en) Treating dyspnea associated with acute heart failure with relaxin
CU20100225A7 (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
AU2013201629B2 (en) Treating dyspnea associated with acute heart failure with relaxin
UA93416C2 (ru) Способ оценки симптомов преждевременной эякуляции
UA69733U (ru) Способ диагностики диастолической дисфункции левого желудочка у больных с неосложненной гипертонической болезнью
UA56675U (ru) Способ местного лечения генерализованного пародонтита c использованием синглетно-кислородной терапии
RU2007140029A (ru) Способ лечения хронической сердечной недостаточности
UA41106U (ru) Способ лечения гипостатической пневмонии у больных с хронической сердечной недостаточностью
UA53527U (ru) Способ комплексного лечения хронической сердечной недостаточности у больных пожилого возраста с ишемической болезнью сердца
UA63268U (uk) Спосіб імуностимуляції у короткозорих людей